MRC1 and cancer: Recommendation 4 accommodates for the identification of a heterozygous (likely) pathogenic variant in one of the MMR genes in a cancer patient aged < 18 years by germline whole exome or whole genome sequencing, which is performed with increasing frequency in paediatric cancer patients [46].